Mechanisms of apoptosis in T cells from patients with renal cell carcinoma

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1219-1229

  Uzzo, Robert G ^a   Rayman, Patricia ^a   Kolenko, Vladimir ^a   Clark, Peter E ^a   Bloom, Tracy ^a   Ward, A Michelle ^a   Molto, Luis ^a   Tannenbaum, Charles ^a   Worford, Lydia J ^a   Bukowski, Ronald ^a   Tubbs, Raymond ^a   Hsi, Eric D ^a   Bander, Neil H ^b   Novick, Andrew C ^a   Finke, James H ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEUKEMIA CELL LINE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD95; APOPTOSIS; BLOOD CELLS; CARCINOMA, RENAL CELL; DNA FRAGMENTATION; FAS LIGAND PROTEIN; HUMANS; IN SITU NICK-END LABELING; IONOMYCIN; JURKAT CELLS; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE GLYCOPROTEINS; MUROMONAB-CD3; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; T-LYMPHOCYTES, CYTOTOXIC; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 0032927310     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Finke, J. H., Rayman, P., Hart, L., Alexander, J. P., Edinger, M. G., Tubbs, R. R., Klein, E., Tuason, L., and Bukowski, R. M. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-γ secretion, and proliferation. J. Immunother., 75: 91-104, 1994.
2. Roszman, T., Elliott, L., and Brooks, V. V. Modulation of T-cell function by gliomas. Immunol. Today, 12: 370-374, 1991.
3. Miescher, S., Stoeck, M., Qiao, L., Barras, C., Barrelet, L., and von Fliedner, V. Preferential clonogenic deficit of CD8-positive T-lyrnphocytes infiltrating human solid tumors. Cancer Res., 48: 6992-6998, 1988.
4. + T cells. J. Immunol., 149: 949-956, 1992.
5. Yoshino, I., Yano, T., Murata, M., Ishida, T., Sugimachi, K., Kimura, G., and Nomoto, K. Tumor-reactive T-cells accumulate in lung cancer tissues but tail to respond due to tumor cell-derived factor. Cancer Res., 52: 775-781, 1992.
6. Alexander, J. P., Kudoh, S., Melsop, K. A., Hamilton, T. A., Edinger, M. G., Tubbs, R. R., Sica, D., Tuason, L., Klein, E., Bukowski, R. M., and Finke, J. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res., 53: 1380-1387, 1993.
7. Miescher, S., Stoeck, M., Qiao, L., Barras, C., Barrelet, L., and von Fliedner, V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int. J. Cancer, 42: 659-666, 1988.
8. O'Connell, J., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med., 184: 1075-1082, 1996.
9. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., and Dietrich, P. Y. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J. Clin. Investig., 99: 1173-1178, 1997.
10. Walker, P. R., Saas, P., and Dietrich, P. Y. Role of Fas ligand (CD95L) in immune escape - the tumor strikes back. J. Immunol., 158: 4521-4524, 1997.
11. Lowin, B., Hahne, M., Mattmann, C., and Tschopp, J. Cytolytic T-cell cytotoxicity is mediated through perform and Fas lytic pathways. Nature (Lond.), 370: 650-652, 1994.
12. Kagi, D., Vignaux, F., Ledermann, B., Burki, K., Depraetere, V., Nagata, S., Hengartner, H., and Goldstein, P. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science (Washington DC), 265: 528-530, 1994.
13. Alderson, M. R., Tough, T. W., Davis-Smith, T., Braddy, S., Falk, B., Schooley, K. A., Goodwin, R. G., Smith, C. A., Ramsdell, F., and Lynch, D. H. Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med., 181: 71-77, 1995.
14. Daniel, P. T., and Krammer, P. H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol., 152: 5624-5628, 1994.
15. Castro, J. E., Listman, J. A., Jacobson, B. A., Wang, Y., Lopez, P. A., Ju, S., Finn, P. W., and Perkins, D. L. Fas modulation of apoptosis during negative selection of thymocytes. Immunity, 5: 617-627, 1996.
16. Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., and Ferguson, T. A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (Washington DC), 270: 1189-1191, 1995.
17. French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Muller, C., and Tschopp, J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol., 133: 335-343, 1996.
18. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997.
19. Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. Melanoma cell expression of Fas(Apo-1/ CD95) ligand: implications for tumor immune escape. Science (Washington DC), 274: 1363-1366, 1996.
20. Shiraki, K., Tsuji, N., Shioda, T., Isselbacher, K. J., and Takahashi, H. Expression of Fas ligand in liver metastases of human colonic adenocarcinoma. Proc. Natl. Acad. Sci. USA, 94: 6420-6425, 1997.
21. Gratas, C., Tohma, Y., Barnas, C., Taniere, P., Hainaut, P., and Ohgaki, H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of fas expression in human esophageal cancer. Cancer Res., 58: 2057-2062, 1998.
22. Bennett, M. W., O'Connell, J., O'Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., Shanahan, F. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with fas ligand expression in human esophageal carcinoma. J. Immunol., 160: 5669-5675, 1998.
23. Rabinowich, H., Reichert, T. E., Kashii, Y., Gastman, B. R., Bell, M. C., and Whiteside, T. L. Lymphocyte apoptosis induced by fas ligand-expressing ovarian carcinoma cells. J. Clin. Investig., 101: 2579-2588, 1998.
24. Strand, S., Hofmann, W. J., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S. M., Stremmel, W., Krammer, P. H., and Galle, P. R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med., 2: 1361-1366, 1996.
25. Zeytun, A., Hassuneh, M., Nagarkatti, M., and Nagarkatti, P. S. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood, 90: 1952-1959, 1997.
26. Lanier, L. L., Allison, P. J., and Phillips, J. H. Correlation of cell surface antigen expression on human thymocytes by multicolor flow cytometric analysis: implications for differentiation. J. Immunol., 137: 1209-1214, 1986.
27. Genestier, L., Fournel, S., Flacher, M., Assossou, O., Revillard, J. P., and Bonnefoy-Berard, N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood, 91: 2360-2368, 1998.
28. Enari, M., Hug, H., and Nagata, S. Involvement of ICE-like protease in Fas-mediated apoptosis. Nature (Lond.), 375: 78-81, 1995.
29. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Feng, L., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 17: 1675-1687, 1998.
30. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M.. Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry, 13: 795-808, 1992.
31. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
32. Dhein, J., Walczak, H., Baumler, C., Debatin, K. M., and Krammer, P. H. Autocrine T cell suicide mediated by Apo-1/(Fas/CD95). Nature (Lond.), 373: 438-441, 1995.
33. Brunner, T., Mogil, R. J., LaFace, D., Yoo, N. J., Mahboubi, F., Echeverri, F., Martin, S. J., Force, W. R., Lynch, D. H., Ware, C. F., and Green, D. R. Cell-autonomous Fas (CD95)/Fas ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature (Lond.), 373: 441-444, 1995.
34. Ju, S. T., Panka, D. J., Cui, R., Ettinger, R., El-Khatib, M., Sherr, D. H., Stanger, B. Z., and Marshak-Rothstein, A. Fas (CD95)/Fas-L interactions required for programmed cell death after T cell activation. Nature (Lond.), 373: 444-448, 1995.
35. Finke, J. H., Tubbs, R., Connelly, B., Pontes, E., and Montie, J. Tumor infiltrating lymphocytes in patients with renal cell carcinoma. Ann. N. Y. Acad. Sci., 532: 387-394, 1988.
36. Zhuang, J., Ren, Y., Snowden, R. T., Zhu, H., Gogvadze, V, Savill, J. S., and Cohen, G. Dissociation of phagocyte recognition of cells undergoing apoptosis from other features of the apoptotic program. J. Biol. Chem., 273; 15628-15632, 1998.
37. Li, X., Liu, J., Park, J. K., Hamilton, T. A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R., and Finke, J. T cells from renal carcinoma patients exhibit an abnormal pattern of κB-specific DNA binding activity: a preliminary report. Cancer Res., 54: 5424-5429, 1994.
38. Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R. R., Novick, A., Finke, J. H., and Bukowski, R. M. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J. Immunol., 20: 479-487, 1997.
39. lck in T-cells infiltrating human renal cell carcinoma. Cancer Res., 53: 5613-5616, 1993.
40. Kolenko, V., Wang, Q., Riedy, M. C., O'Shea, J., Ritz, J., Cathcart, M. K., Rayman, P., Tubbs, R., Edinger, M., Novick, A., Bukowski, R., and Finke, J. Tumor-induced suppression of T lymphocytes coincides with inhibition of Jak3 expression and IL2 receptor signaling. J. Immunol., 159: 3057-3067, 1997.
41. Tanaka, M., Suda, T., Haze, N., Nakamura, K., Sato, F., Kimura, K., Motoyoshi, M., Mizuki, S., Tagawa, S., Ohga, S., Hatake, K., Drummond, A. H., and Nagata, S. Fas ligand in human serum. Nat. Med., 2: 317-322, 1996.
42. Niehans, G. A., Brunner, T., Frizelle, S. P., Liston, J. C., Salerno, C. T., Knapp, D. J., Green, D. R., and Kratzke, R. A. Human lung carcinoma express Fas ligand. Cancer Res., 57: 1007-1012, 1997.
43. Smith, D., Sieg, S., and Kaplan, D. Technical note: aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J. Immunol., 160: 4159-4160, 1998.
44. Wang, Q., Redovan, C., Tubbs, R., Olencki, T., Klein, E., Kudoh, S., Finke, J., and Bukowski, R. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes. Int. J. Cancer, 61: 780-785, 1995.
45. Pisa, P., Halapi, E., Pisa, E. K., Gerdin, E., Hising, C., Bucht, A., Gerdin, B., and Kiessling, R. Selective expression of interleukin 10, interferon-γ, and granulocyte-macrophage colony stimulating factor in ovarian biopsies. Proc. Natl. Acad. Sci. USA, 89: 7708-7712, 1992.
46. Cardi, G., Heaney, J. A., Schned, A. R., and Ernstoff, M. S. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res., 58: 2078-2080, 1998.
47. + cells and apoptosis suppress T cell functions in multiple myeloma. Br. J. Haematol., 100: 469-477, 1998.
48. Moss, D. J., Burrows, S. R., Baxter, G. D., and Lavin, M. F. T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism. J. Exp. Med., 173: 681-686, 1991.
49. Kabelitz, D., Oberg, H. H., Pohl, T., and Pechhold, K. Antigen induced death of mature T lymphocytes: analysis by flow cytometry. Immunol. Rev., 142: 157-174, 1994.
50. Uzzo, R. G., Clark, P. E., Rayman, P., Bloom, T., Rybicki, L., Novick, A. C., Bukowski, R. M., and Finke, J. H. Alterations in NFκB activation in T lymphocytes of patients with RCC. J. Natl. Cancer Inst., in press, 1999.
51. Wang, C., Mayo, M. W., and Baldwin, A. S. TNF and cancer therapy induced apoptosis: potentiation by inhibition of NF-κB. Science (Washington DC), 274: 784-787, 1996.
52. Beg, A. A., and Baltimore, D. An essential role for NFκB in preventing TNF-α induced cell death. Science (Washington DC), 274: 782-784, 1996.